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Abstract
PD184352/CI-1040 is a potent and selective MEK1/2 in-
hibitor that represents the first MEK-targeted agent to
enter clinical trials. Here, we report the development
and molecular characterization of CI-1040 resistance in
the murine colon 26 (C26) carcinoma cell line. The
growth rate of the resistant line (C26/CI-1040r) in the
presence of 2 MM CI-1040 is comparable to that of pa-
rental C26 cells in the absence of CI-1040. C26/CI-1040r
cells are approximately 100-fold more resistant than
the parental line to CI-1040 inhibition in soft agar and
are less sensitive to the induction of apoptosis that nor-
mally occurs in response to CI-1040 treatment. K-ras
expression is significantly elevated in C26/CI-1040r
cells. We confirmed a causative role for K-ras in con-
ferring resistance to CI-1040 by transfecting K-ras into
parental C26 cells, whereupon an elevation in the levels
of phosphorylated ERK1/2 was observed in addition to
resistance to CI-1040. Furthermore, an in vivo–derived
MEK inhibitor–resistant line also shows increased
K-ras expression. Our data suggest that increasing
activated K-ras expression represents one potential
mechanism by which tumor cells that initially are
responsive to blockade of the MAP kinase pathway
can overcome their sensitivity to MEK inhibition.
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Introduction
Ras is one of the most frequently mutated oncogenes in
human cancers. Approximately 30% of all human cancers
contain an activating Ras mutation [1]. The incidence of
K-ras mutations is particularly high in pancreatic and colon
cancers (90% and 44%, respectively) [1,2]. Active Ras
directly binds to and regulates the function of numerous
downstream targets, including Raf kinase, phosphotidy-
linositol 3-kinase (PI3K), RalGDS, MEKK1, and others. Raf
is the best-characterized downstream effector of Ras and
plays a critical role inRas biology [3]. HowRas activates Raf
is not completely understood. However, it is believed that
Ras binding results in membrane localization of Raf and
thus leads to subsequent phosphorylation and activation
of Raf [4]. Active Raf directly phosphorylates and activates
the MAP kinase kinase referred to as MEK. MEK phosphor-
ylates ERK on both threonine and tyrosine residues in the acti-
vation loop, resulting in an approximate 3000-fold activation
of ERK. The Raf–MEK–ERK cascade is a signaling paradigm
for many MAP kinase cascades, which regulate a wide array
of cellular activities in diverse species ranging from yeasts to
humans [5,6].
The Raf–MEK–ERK kinase cascade plays an essential
role in cell proliferation. Inhibition of this pathway can block
oncogenic transformation by Ras [5,6]. The importance of this
pathway in human carcinogenesis is further supported by the
recent observation that B-Raf is a human oncogene [7].
Activating mutations of B-Raf have been found in approxi-
mately 66% of human melanomas [7]. Given the central
function of the Raf–MEK–ERK pathway in cell proliferation,
extensive efforts have been devoted to developing inhibitors of
this pathway in the hope of developing improved molecular-
targeted anticancer therapies [1,8,9]. We previously reported
the identification and evaluation of a potent and selective MEK
inhibitor, PD184352 (CI-1040) [10]. This compound is orally
active and has been shown to suppress ERK phosphorylation
in vivo, thereby resulting in broad-spectrum activity against a
diverse panel of human and murine tumor xenografts. Inter-
estingly, CI-1040 did not exhibit any overt signs of clinical
toxicity [10]. CI-1040 was advanced into clinical testing in
cancer patients and represents the first MEK inhibitor to enter
clinical development [11–13]. In this report, we have isolated a
CI-1040–resistant clone (C26/CI-1040r) from the mouse colon
carcinoma cell line C26, which is known to contain a K-rasV12
mutation. Resistance was obtained by culturing cells in the
presence of gradually increasing concentrations of CI-1040
over a 6-month time period. The growth rate of C26/CI-1040r in
the presence of 2 mM CI-1040 is similar to parental C26 cells
grown in its absence. C26/CI-1040r cells are resistant to cell
cycle arrest and apoptosis in response to CI-1040 treatment.
RNA expression profiling indicates that the resistant cells have
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a high level of K-rasV12 expression. Furthermore, a CI-
1040–resistant line was also derived from C26 tumors
treated in vivo with a CI-1040 analog (PD0325901), and
these resistant cells similarly display an elevation in
K-rasV12 expression. Consequently, studies were carried
out to overexpress K-rasV12 in C26 parental cells, where-
upon resistance to CI-1040 was conferred. Our data suggest
that elevated expression of K-ras is at least partially respon-
sible for the resistance of murine C26 colon carcinoma cells
to the MEK inhibitor CI-1040 reported here.
Materials and Methods
Cell Culture
The C26 mouse colon carcinoma cell line was cultured
in DMEM/F12 medium supplemented with 10% FBS and
20 mg/ml gentamicin. C26/CI-1040r cells were grown in the
same growth medium as parental C26 cells but were contin-
uously maintained in the presence of 2 mM CI-1040. All cells
were incubated at 37jC with 5% CO2.
Creating the Resistant C26 Cell Line
Exponentially growing C26 cells were initially exposed to
0.1 mM CI-1040. The concentration of CI-1040 was gradually
increased to a final concentration of 2 mM over a 6-month
time period. Cells were then serially diluted in a 96-well plate
until a single colony isolate could be obtained. Selective
pressure for CI-1040 resistance was maintained by continu-
ous exposure of this isolate (referred to as C26/CI-1040r) to
2 mM CI-1040.
Soft Agar Assays
Cells were plated in 2 DMEM-F12 growth medium
supplemented with 20% fetal bovine serum at a density of
2  104 cells/well in six-well plastic dishes. A two-layer agar
system was used, in which the final concentrations of Bacto-
Agar (Difco Laboratories, Detroit, MI) were 0.6% and 0.3%
in the bottom and top layers, respectively. After incubation of
the samples for 7 days, 1ml of 1mg/ml p-iodonitrotetrazolium
violet (Sigma, St. Louis, MO) was added to each well for an
additional 24 hours to visualize the colonies. Colonies con-
tainingmore than 50 cells were quantitated by phase contrast
microcopy (Nion, Meville, NY) using the public domain NIH
program developed at the US National Institutes of Health
(available at http://rsb.info.nih.gov/nih-image/).
[14C]Thymidine Incorporation
Five hundred cells were plated per well in a 96-well
CytoStar plate (cat no. RPNQ 0162; Amersham, Piscataway,
NJ) in 100 ml of DMEM/F12 with 10% FBS and 20 mg/ml
gentamicin. On the next day, cells were fed with 100 ml of
freshmediumwith the indicated concentration of CI-1040 and
0.1 mCi of [14C]thymidine and cultured in a 37jC incubator
with 5% CO2 for 7 days. Quantitation of counts was deter-
mined daily for 6 days after [14C]thymidine addition, using a
Wallac microbeta counter.
Apoptosis Assay
Roche’s Cell Death Detection ELISAplus kit (cat no. 1 774
425) was used for apoptotic measurement. The 96-well plate
assay detects the amount of fragmented DNA, a hallmark of
apoptosis. Briefly, 5000 C26 parental or C26/CI-1040r cells
were plated per well in 96-well tissue culture plates or
polyHEMA-coated plates. One day after plating, cells were
treated with the indicated concentration of CI-1040. Cells
were harvested for the apoptosis assay 24 hours after
CI-1040 treatment according to procedures provided by
the manufacturer.
Cell Cycle Analysis
C26 parental or C26/CI-1040r cells were plated in six-well
plates at 1  105 cells/well in DMEM/F12 with 10% FBS and
20 mg/ml gentamicin. On the following day, the cells were
treated with the indicated concentration of CI-1040 for
24 hours. At the time of cell harvesting, both floating and
attached cells were combined. The cells were first centri-
fuged at 2000 rpm for 5 minutes to remove the medium.
Pellets were washed once with PBS and then resuspended in
0.5ml of PBSwith 0.1% FBS. The cells were added dropwise
to 75% ice-cold ethanol. After fixing for 1 hour at 4jC, the
cells were then centrifuged at 2000 rpm for 5 minutes,
washed once in PBS with 0.1% FBS, and then treated with
0.5 ml of PBS with 0.2 mg/ml RNAse A and 50 mg/ml
propidium iodide (PI) for 30 minutes at 37jC. The RNase A/
PI–treated cells were passed through a 5-ml strainer capped
tube and the cell cycle distribution was determined using the
BD LSR as described previously [14]. The cell cycle distribu-
tion was analyzed with ModFit LT (AMPL Software Pty Ltd.,
Turramurra, NSW, Australia) and the pre-G1 population was
analyzed with CellQuest (BD Sciences, San Jose, CA).
Immunoblotting, Immunoprecipitation, and Kinase Assays
For immunoblots, cells were plated in 12-well or 6-well
plates as described above. One day after plating, cells were
treated with the indicated concentration of CI-1040 or DMSO
for 1 hour. The cells were quickly washed once with PBS
containing 0.1 mM Na3VO4 and lysed in 200 ml of lysis buffer
(50 mM glycerol phosphatate, 10 mM Hepes, pH 7.4, 1%
Triton X-100, 70 mMNaCl, 1 mM sodium vanadate, and 40 ml
of Roche’s complete proteinase cocktail per milliliter) per well
for 12-well plates or 500 ml/well for six-well plates. After
transferring the lysate to a 1.5-ml eppendorf tube, incuba-
tion at 4jC occurred for an additional 15 minutes. The cells
were then centrifuged at 10,000 rpm for 10 minutes to collect
the supernatant. Immunoblots were performed as described
previously [14] with 1% BSA and 1% ovalbumin in 50 mM
Tris, pH 7.5, 150 mM NaCl, and 0.05% Tween-20. For Ras
immunoprecipitation, equal amounts of each cell lysate were
incubated with 40 ml of agarose-conjugated pan-Ras anti-
body (sc-35AC; Santa Cruz Biotechnology, Santa Cruz, CA)
in a final volume of 0.5 ml for 2 hours at 4jC with rotation.
The immunoprecipitated samples were then washed five
times with cell lysis buffer and each sample was re-
suspended in 30 ml of SDS sample buffer. The immuno-
precipitated samples were resolved on 4% to 20% Novex
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SDS gradient gel and blotted with K-ras–specific antibody
(sc-30; Santa Cruz Biotechnology). For MEK1/2 immuno-
precipitation kinase assay, equal amounts of C26 parental
or resistant cell lysates were incubated with 20 ml of anti-
MEK1 antibody (sc-219; Santa Cruz Biotechnology) or 20 ml
of agarose-conjugated anti-MEK2 antibody (sc-524AC;
Santa Cruz Biotechnology). After a 2-hour incubation at
4jC, 40 ml of protein A/G plus agarose was added to the
MEK1-immunoprecipitated cell lysate and incubated for
another hour. The immunoprecipitates were then washed
five times with cell lysis buffer and twice with kinase buffer
(25 mM Hepes, pH 7.5, 5 mM MgAc2). Each immuno-
precipitated sample was resuspended in kinase buffer with
250 mM cold ATP, 2 mCi of [r-32P] ATP (the indicated
concentration of CI-1040), and 0.1 mM GST-ERK1K71R for
30 minutes at room temperature. The reaction samples were
then resolved on 8% Novex SDS gel and subjected to X-ray
radiography exposure.
Ras Activation Assay
Upstate’s Ras Activation kit (cat no. 17-218) was used for
Ras-GTP measurements. Briefly, agarose-conjugated Raf-1
RBD (Ras binding domain, or RBD) was employed to spe-
cifically bind and precipitate the GTP bond form of Ras from
cell lysates. The precipitated Ras-GTP was then resolved on
an SDS gel and detected with anti-Ras antibody. The cells
were first lysed in lysis buffer as described above and 500 mg
of each cell lysate in 100 ml of lysis buffer was incubated with
400 ml of MLB buffer provided in the kit. The remaining steps
were carried out according to the procedure recommended
by the manufacturer.
Selection of K-rasV12 Stable Clones
C26 parental cells were transfected with pZip K-rasV12
with lipofectamine 2000 according to the protocol suggested
by the manufacturer (cat no. 11668-027; Invitrogen, Carls-
bad, CA). Specifically, 4 mg of pZip K-rasV12 in 250 ml of
Opti-MEM was mixed with 10 ml of Lipofectamine 2000 in
250 ml of Opti-MEM. After a 20-minute incubation, the DNA/
Lipofectamine 2000 mixture was added to 90% confluent
C26 parental cells. The transfection was stopped 24 hours
later by feeding cells with fresh medium. The cells were then
replated 1 day after transfection as 10-, 100-, and 1000-fold
dilutions in 150-mm cell culture dishes with 750 mg/ml
G418 in the presence or absence of 2 mM CI-1040. The
cells were fed with fresh medium with G418 twice during a
17-day period for colony formation. Individual clones were
picked up with cloning cylinders and grown in the same
manner as described previously. CI29 refers to the Ras-
transfected colonies selected in the presence of 2 mM CI-
1040, and 33 designates the colonies selected in the
absence of CI-1040.
Cell Pictures and Cell Counting
A total of 50,000 cells/well was plated in a six-well plate.
On the next day, the plated cells were treated with DMSO or
2 mM CI-1040 for 2 days. Pictures were taken 2 days after
compound treatment. Cell counts were determined on a
Coulter Counter (Beckman Coulter, Inc., Fullerton, CA) on
days 1, 2, and 3 after cell plating.
RNA Preparation
Approximately 2  106 C26 parental and resistant cells
were seeded into T150 flasks, respectively. Once cells
reached approximately 80% confluence, they were treated
with either DMSO or 0.3 mM CI-1040 for 1 or 24 hours. The
total RNA was isolated from both the parent and resistant
lines by first washing the cells in PBS, and then adding 3ml of
a reagent consisting of 25mM sodium citrate, 0.5% Sarkosyl,
4 M guanidium thiocyanate, and 0.7% 2-mercaptoethanol to
solubilize the cell monolayer. Solutions were transferred to
14-ml snap-cap tubes and another 3 ml of the above reagent
was added to the flask for a final rinse. The solution in each
14-ml tube was then split into two tubes and 3 ml of phenol
and 600 ml of chloroform IAA were added and mixed vigor-
ously, and the tube was placed on ice for 15 minutes. All the
tubes were centrifuged at 8000 rpm for 20 minutes at 4jC.
The aqueous phase was transferred to a second 14-ml tube,
3 ml of chloroform IAA was added, and the tubes were mixed
vigorously and then centrifuged at 8000 rpm for 10minutes at
4jC. Again, the aqueous phase was transferred to another
clean tube, an equal volume of isopropyl alcohol (f3ml) was
added, and tubes were mixed and placed at 20jC over-
night. Tubes were removed from 20jC and centrifuged at
8000 rpm for 10 minutes at 4jC. Immediately following the
centrifugation, the liquid was aspirated and the pellet was
dissolved in 300 ml of the abovementioned reagent. The RNA
was transferred to an autoclaved 1.5-ml centrifuge tube, and
the 14-ml tube was rewashed with another 300 ml of the
reagent mentioned above and then combined with the first
wash. An equal volume of isopropyl alcohol was added to the
RNA; the tubes were mixed and placed at 20jC for 1 hour.
Tubes were then centrifuged at 2000g for 3 minutes at 4jC.
Following centrifugation, the liquid was aspirated and 500 ml
of 70% ethanol was added. Tubes were then vortexed and
centrifuged at 2000g for 3 minutes at 4jC. Pellets were
dissolved in 75 ml of DEPC–water.
Affymetrix Gene Chip Profiling
cRNA was synthesized from the total RNA and then
subjected to chip hybridization as detailed previously [15].
The Affymetrix (Santa Carla, CA) mouse genome U74Av2
array was used for RNA expression profiling. Briefly, double-
stranded cDNA was prepared from the RNA template using
a modified oligo-dT primer containing a 5V T7 RNA polymer-
ase promoter sequence and the Superscript Choice System
for cDNA Synthesis (Life Technologies, Inc., Gaithersburg,
MD). Following phenol–chloroform extraction and ethanol
precipitation, one-half of the cDNA reaction (0.5–1.0 mg) was
used as the template in an in vitro transcription reaction
containing T7 RNA polymerase;, a mixture of unlabeled
ATP, CTP, GTP, and UTP; and biotin-11-CTP and biotin-
16-UTP (BioArray High Yield Kit; ENZO, Inc., Farmingdale,
NY). The resulting biotinylated cRNA ‘‘target’’ was purified
on an affinity resin (RNeasy; Qiagen, Valencia, CA) and
quantified using the convention that 1 OD260 corresponds to
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40 mg/ml RNA. Fifteen micrograms of biotinylated cRNA was
randomly fragmented to an average size of 50 nucleotides by
incubating at 94jC for 35 minutes in 40 mM Tris–acetate, pH
8.1, 100 mM potassium acetate, and 30 mM magnesium
acetate. The fragmented cRNA was hybridized in a solution
containing 100 mM MES, pH 6.6, 1 M [Na+], 20 mM EDTA,
0.01% Tween 20, 50 pM of control oligonucleotide B2 (Affy-
metrix), 0.1 mg/ml of sonicated herring sperm DNA, and
0.5 mg/ml BSA for 16 hours at 45jC on the MG-U74Av2
genechips. Scanned output files were analyzed using Affy-
metrix’s software Microarray Suite 5.0.
Data Extraction and Comparison Analysis
All data sets from each gene chip were normalized to a
target intensity of 600. The new statistical algorithms were
used to generate signal and detection in the Microarray Suite
5.0. The fold change was calculated between parent and
resistant samples using the average of the signals between
the duplicates. A two-fold change cutoff was used to filter out
genes with insignificant changes. The list of common genes
with changes of at least two-fold between resistant and
parental cell lines treated in the presence or absence of
CI-1040 at 1- and 24-hour time point was generated.
Development of In Vivo Resistance to MEK Inhibition
During the course of an extended treatment regimen
(28-day treatment) of C26-bearing mice with PD0325901, a
structurally related analog of CI-1040, tumors initially
regressed to below the limit of palpation, but then regrew
while still under treatment. The tumor from one mouse that
Figure 1. C26/CI-1040r cells are resistant to the growth-inhibitory effects of CI-1040. (A) Dose response of CI-1040 in C26/CI-1040r and its parental cell line C26 in
a soft agar growth assay. (B) Cell morphology and cell density of C26 and C26/CI-1040r in cell culture. Cells were seeded in six-well plates at 50,000 cells/well. One
day after cell plating, the cells were treated with DMSO or 2 M CI-1040 for 2 days. (C) Effect of CI-1040 on cell monolayer growth. After pictures were taken as
shown in (B), both floating and attached cells were combined and then counted with a Coulter Counter. (D–F) Effect of CI-1040 on C26 parental cell growth was
measured by [14C]thymidine incorporation.
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had received the highest dose (25 mg/kg, which is equiva-
lent to the maximum tolerated dose of PD0325901) was
transplanted into recipient mice. Daily dosing with
PD0325901 at 25 mg/kg was initiated 10 days after tumor
implantation. Several of the most drug-resistant tumors
were excised and transplanted again. This selection pro-
cess was repeated, becoming more stringent (beginning
dosing 8 days, and then 4 days after tumor implantation)
for four more passages in BALB/c mice. This tumor line
was serially transplanted eight more times without drug
pressure before being used in the study reported here.
This line exhibited a tumor doubling time comparable to
that of the parental C26 line.
Animal Efficacy Studies
Tumor fragments (approximately 3 mm3 in size) of either
parental C26 or C26/PD0325901r were implanted subcuta-
neously into the right subaxillary region of young adult,
female, BALB/c mice. Treatment administered by oral ga-
vage was initiated when tumors reached a mass of approxi-
mately 200 mg. CI-1040 was prepared at 300 mg/kg in a
vehicle of 0.5% hydroxypropylmethylcellulose, plus 0.2%
Tween 80 in water. Tumor size was evaluated periodically
by caliper measurements, generally three times per week. A
complete response is defined as a tumor that decreased in
mass to below the limit of palpation (62 mg) during the study.
A partial response represents a tumor that decreased by a
least 50% of its initial mass during the study. T and C are
defined as the times required for treated and control tumors,
respectively, to reach 750 mg.
Results
Isolation and Characterization of a CI-1040–Resistant
Cell Line
We have previously reported that the MEK inhibitor
CI-1040 inhibited both human and mouse colon carcinoma
growth. Growth of C26 tumors in vivo was inhibited up to
79% with no signs of toxicity, and tumor growth inhibition
correlated with a reduction in the levels of phosphorylated
ERK (pERK) in excised tumors [10]. CI-1040 inhibited
anchorage-independent growth of C26 cells with an IC50 of
0.15 mM, similar to the degree of MEK inhibition observed
when these cells were treated with CI-1040. To isolate drug-
resistant cells, C26 parent cells were cultured in the pres-
ence of gradually increasing concentrations of CI-1040
starting at 0.1 mM. Six months after initiation of these
studies, a single clone, C26/CI-1040r, was isolated from a
cell population growing at the parental growth rate in the
presence of 2 mM CI-1040.
Soft agar assays confirmed the resistance of C26/CI-
1040r to the MEK inhibitor, CI-1040 (Figure 1A). The anchor-
age-independent growth of parental C26 cells was impaired
Figure 1. (Continued)
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in a dose-dependent manner. At a concentration of 1 mM, CI-
1040 inhibited colony formation of parental C26 cells by
>80% (Figure 1A). In contrast, no inhibition of colony forma-
tion was observed when resistant C26/CI-1040r cells were
plated at concentrations <3 mM (Figure 1A). Surprisingly, we
consistently observed a significant increase in the number of
CI-1040–resistant colonies (approximately 100% increase)
when the inhibitor concentration was lower than 3 mM. A
much higher concentration of the inhibitor (30 mM) was
required to inhibit the growth of the C26/CI-1040r line.
Morphologic assessment also revealed that C26/CI-1040r
cells show a more transformed phenotype than parental cells
(Figure 1B). C26/CI-1040r cells are more reflective, elon-
gated, and less attached—properties that are also charac-
teristic of Ras-transformed cells. Treatment with CI-1040
resulted in morphologic reversion of the resistant cells to the
parental phenotype (compare panels a and d in Figure 1B).
Quantification of cell counts showed that 2 mM CI-1040
inhibited the cell growth of parental cells by 60%, whereas
the same concentration of inhibitor stimulated the growth of
resistant cells by 45% relative to DMSO controls (Figure 1C),
consistent with observations obtained in the anchorage-
independent growth assays.
To determine the proliferation rate, DNA synthesis was
measured by [14C]thymidine incorporation (Figure 1, D–F).
CI-1040 inhibited the DNA synthesis of parental cells in a
dose-dependent manner, even at the lowest concentration
(0.1 mM) tested (Figure 1D). In contrast, CI-1040 slightly en-
hanced DNA synthesis in the resistant line when the inhibi-
tor concentration was low. Higher concentrations of CI-1040
eventually inhibited the DNA synthesis of C26/CI-1040r cells.
These results suggest that the proliferation of C26/CI-1040r
cells is less sensitive to inhibition by CI-1040 than parental
cells. In fact,C26/CI-1040r cells growmore favorablywhen low
concentrations of CI-1040 are present in the growth medium.
C26/CI-1040r Cells Are Resistant to Apoptosis Induced
by the MEK Inhibitor, CI-1040
We also investigated the effect of CI-1040 on apoptosis.
Cell death was measured in both the parental and resistant
cell lines grown in the presence of varying concentrations
of CI-1040. In parental cells, significant apoptosis was ob-
served at CI-1040 concentrations exceeding 0.4 mM, with
maximum apoptosis observed at 1.6 mM (Figure 2A). In com-
parison, low concentrations of CI-1040 did not cause a
significant increase of apoptosis in C26/CI-1040r cells. The
concentration of CI-1040 required to elicit an equivalent
degree of apoptosis in the resistant cell line relative to the
parental line was approximately 10-fold higher (Figure 2A).
We followed up on this finding by testing for sensitivity to apo-
ptosis induction by CI-1040 under anchorage-independent
growth conditions. Due to the difficulty in isolating cells from
soft agar, C26 cells were grown on polyHEMA-coated plates
to prevent cell adherence. As shown in Figure 2B, C26 cells
were much more sensitive to CI-1040–induced apoptosis
than C26/CI-1040r cells. In addition, we found that non-
adhering conditions enhanced the sensitivity of C26 cells to
CI-1040–induced apoptosis (compare Figure 2, A and B).
The difference was particularly evident at low concentrations
of the inhibitor (i.e., 0.1 mM).
The effect of CI-1040 on cell proliferation and apoptosis
was further determined by flow cytometry analysis. CI-1040
treatment for 24 hours caused a G1 cell cycle arrest in C26
cells concordant with a decrease of S and G2/M phase cells
(Figure 3). Similarly, the apoptotic cell population (pre-G1
cells) was increased in cells treated with CI-1040 at con-
centrations z0.5 mM. In contrast, C26/CI-1040r cells were
much less sensitive to CI-1040 with respect to both growth
arrest and apoptosis under the same treatment conditions
(Figure 3).
C26/CI-1040r Cells Exhibit Elevated ERKPathway Activation
But Are Still Sensitive to Inhibition by CI-1040
To determine the mechanism of CI-1040 resistance, we
examined the activation status of ERK. Western blotting
with an antiphosphoERK antibody demonstrated that the
resistant cells have a much higher level of active ERK than
the parental cells (Figure 4, A and C). Treatment with
CI-1040 inhibited phosphoERK expression in both the pa-
rental and resistant cells. In fact, both the parental and
resistant cells showed a similar dose response to CI-1040
Figure 2. The C26/CI-1040r cell line is less sensitive to CI-1040– induced
apoptosis. Cells were plated on regular or polyHEMA-coated 96-well tissue
culture plates. One day after cell plating, the cells were treated with the
indicated concentration of CI-1040. The cells were then harvested for the
apoptosis assay 24 hours after compound treatment. (A) Apoptosis assay
for C26 and C26/CI-1040r cells grown on regular tissue culture plates. (B)
Apoptosis assay for C26 and C26/CI-1040r cells grown on polyHEMA-coated
96-well plates.
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Figure 3. C26/CI-1040r is less sensitive to CI-1040– induced cell cycle arrest than the parental C26 cell line. Cells were treated for 24 hours with CI-1040 and then
cell cycle analysis was run on the BD LSR flowcytometer. A total of 25,000 events was collected per analysis.
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(see Figure 4A for comparison of the longer exposure of
C26 parent with shorter exposure of C26/CI-1040r). These
results suggest that the alterations in the resistant cells likely
occur at a step upstream of MEK. To further exclude the
possibility that the resistance is due to a MEK mutation in
C26/CI-1040r cells, MEK1 and MEK2 proteins were inde-
pendently immunoprecipitated with the corresponding anti-
body, and the dose response of the immunoprecipitated
kinases to CI-1040 inhibition was evaluated with purified
kinase inactive ERK1, GST-ERK1K71R, as a substrate.
CI-1040 resulted in a similar dose-dependent inhibition of
both MEK1 and MEK2 in vitro regardless of whether MEK
was isolated from the parental or resistant cells (Figure 4B).
MEK activation status is determined by phosphorylation in
its activation loop and this can be indirectly determined using
a phospho-specific MEK antibody. As shown in Figure 4C,
resistant cells have higher MEK activity than parental cells.
These results suggest that the mutations/alterations in the
resistant cells likely occur at a step before MEK. CI-1040
treatment did not inhibit MEK phosphorylation, supporting the
concept that the MEK inhibitor does not block signal trans-
duction upstream of MEK. Interestingly, treatment with the
MEK inhibitor increased phosphorylation of MEK (Figure 4C).
This observation could be explained by the possibility
that the Ras–ERK pathway is subjected to feedback regu-
lation [16]. By blocking ERK activation and signaling, treat-
ment with CI-1040 could block any feedback regulation
resulting from ERK activation. Such a lack of feedback
inhibition may contribute to the increased phosphorylation
of MEK shown in Figure 4C.
K-ras Is Elevated in CI-1040–Resistant Cells
In an attempt to identify gene(s) that potentially contribute
to the CI-1040–resistant phenotype, we performed RNA ex-
pression profiling analysis. C26 and C26/CI-1040r cells were
treated with 0.3 mM CI-1040 or DMSO for 1 and 24 hours,
respectively. The cells were harvested and total RNA was
prepared. As expected, treatment with CI-1040 for 1 hour did
not cause a significant effect on gene expression in either
C26 parental or resistant cells (data not shown). Interestingly,
over 2000 genes showed a change in expression of two-
fold or greater in C26 cells 24 hours after treatment with
0.3 mM CI-1040. In contrast, only 10 genes were found to
exhibit a two-fold change in C26/CI-1040r cells under the
same conditions (data not shown). A baseline comparison
of C26 parental versus C26/CI-1040r cells grown under the
same treatment condition yielded a list of 25 genes that
changed two-fold (Table 1). Twenty-three of these 25 genes
are known. The expression level of K-ras (the C26 parental
colon cancer cell line contains an active K-rasV12 mutation;
unpublished observation) in the resistant cell line is approxi-
mately 2.5-fold higher than that observed in the parental cell
line (Figure 5A). To further confirm the differential expression
at the protein level, K-ras was immunoprecipitated and de-
tected by an anti–K-rasWestern blot. Our results confirmed
that K-ras protein levels were elevated in the resistant cells
(Figure 5B). To determine the amount of K-ras in the GTP-
bound or active form, a Ras activation assay was performed.
The principle of this assay is that the activated form of
Ras can associate with the RBD of Raf-1. C26 parental
and resistant cell lysates were normalized for protein and
Figure 4. The basal level of ERK1/2 phosphorylation increases in C26/CI-1040r cells, but the sensitivity of MEK1/2 to CI-1040 inhibition is not significantly altered.
(A) Effect of CI-1040 on ERK phosphorylation in C26 and C26/CI-1040r cells. Cells were treated with the indicated concentration of CI-1040 for 1 hour and then
harvested for Western analysis. Two different exposures of the same immunoblots are shown. (B) Effect of CI-1040 on MEK1 and MEK2 in C26 and C26/CI-1040r
cells. MEK1 or MEK2 from C26 or C26/CI-1040r cells was immunoprecipitated with the corresponding antibody. The kinase activities were assayed with GST-
ERK1K71R as substrate as described in the Materials and Methods section. The exposure time was adjusted to give a similar basal level of intensity (without
compound treatment). (C) Effect of CI-1040 treatment on ERK and MEK phosphorylation. C26 (P) and C26/CI-1040r (R) cells were treated with DMSO () or 2 M
CI-1040 (+) as described in the Materials and Methods section.
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precipitated with Raf-1 RBD agarose. The precipitated sam-
ples were then subjected to SDS gel electrophoresis and
probed with the Ras antibody. As shown at Figure 5C, over-
expressed K-ras in C26/CI-1040r cells was also active.
Increased K-ras Expression in an In Vivo–Derived
Resistant Clone
To further investigate the mechanism of resistance to
MEK inhibition, we performed parallel experiments in C26
tumor-bearing mice to isolate a resistant line. BALB/c mice
implanted with C26 cells uniformly develop tumors. Treat-
ment with PD0325901, a structurally related analog of
CI-1040 and a potent MEK inhibitor, typically causes regres-
sion in this tumor model [17]. During an extended treatment
period (28 days), regrowth of tumors was observed in some
animals and a resistant line (C26/PD0325901r) was isolated
as described in the Materials andMethods section. As shown
in Table 2, the C26/PD0325901r line was significantly resis-
tant to CI-1040 treatment in vivo. Growth of C26/PD0325901r
tumors was not inhibited in response to CI-1040 treatment.
In contrast, growth of parental tumors was significantly de-
layed in response to the same CI-1040 treatment regimen
(Table 2). Subsequent examination of the expression level
of K-ras revealed that this protein was elevated in the in
vivo–derived C26/PD0325901r cells (Figure 5D). Consistent
with previous in vitro findings, these observations suggest
a possible role of K-ras in conferring MEK resistance to
MEK inhibitors.
Expression of K-ras Confers C26 Resistance to CI-1040
Elevated expression of K-ras or EGF-like growth factors
could contribute to the resistance phenotype of C26/CI-1040r
cells. It has been reported that Ras activation can induce
the expression of betacellulin, epiregulin, and amphiregulin
[18–20]. The induction of these EGF-like growth factors may
contribute to an autocrine loop and stimulate cell growth in
Ras-transformed cells. Therefore, we focused on K-ras be-
cause the elevated expression of EGF-like growth factors
could be a consequence of K-ras overexpression. K-rasV12
was transfected into the parental C26 cells and stable clones
were isolated under two different conditions. Clones CI29-2,
CI29-13, and CI29-16 were selected in the presence of 2 mM
CI-1040 and G418, which selects for the presence of K-ras
expression plasmids. In a separate group, clones 33-4,
33-10, and 33-11 were selected for G418 alone in the
absence of CI-1040. These separately derived stable clones
were tested for their ability to grow on soft agar in the
presence of CI-1040. As shown in Figure 6A, the three
CI29 clones exhibited complete resistance to 2 mM CI-1040
and the three 33 clones also displayed significant resistance
to 2 mM CI-1040 when compared to C26 parental cells.
Interestingly, the MEK inhibitor significantly enhanced the
growth of both the CI29-13 and CI29-16 clones. These
results demonstrated that K-ras expression may lead to
CI-1040 resistance.
The effect of K-ras expression on ERK activation was
determined. We found that ERK was activated to varying
degrees among the K-ras expression clones. The degree of
ERK activation did not linearly correlate with the degree of
CI-1040 resistance. However, it is worth noting that CI29-13
has the highest ERK activity. This clone also displays a sig-
nificant growth advantage in the presence of MEK inhibitor.
Similarly, clones 33-4 and 33-11 both showed a moderate
increase in ERK activity and less resistance to CI-1040
(Figure 6B). Collectively, our data provide a qualitative cor-
relation between ERK activation by K-ras and resistance
to MEK inhibition.
Discussion
Previous studies have shown that the MEK inhibitor CI-1040
has promising potential to inhibit cancer cell growth [10]. In
Table 1. K-ras and EGF-Like Growth Factors Are Upregulated in C26/CI-
1040r Cells.
Gene Name DMSO Control 0.3 MM CI-1040
1 hr 24 hr 1 hr 24 hr
K-ras 2.197 2.767 2.515 5.04
Epiregulin 5.044 3.493 7.633 11.438
Amphiregulin (schwannoma-
derived growth factor)
6.89 7.156 12.973 18.572
Betacellulin 2.827 9.282 4.667 5.397
Transforming growth factor,
beta-induced, 68 kDa
8.039 2.277 7.758 3.256
Inhibitor of DNA binding 3,
dominant negative
helix – loop–helix protein
10.084 3.716 8.994 6.368
Wingless-type MMTV integration
site family, member 10A
2.492 2.216 2.687 3.649
Interferon-stimulated protein,
20 kDa
2.39 3.52 2.788 11.962
T cell –specific GTPase 4.314 12.942 5.102 22.143
Immunoglobulin heavy chain 6
(heavy chain of IgM)
2.032 3.125 3.073 2.533
Transportin-SR 2.961 2.07 2.099 5.682
Pleckstrin homology, Sec7 and
coiled/coil domains, binding
protein
3.287 3.243 3.831 2.75
Keratin 18 21.004 11.989 28.629 2.98
Testis-derived transcript (three
LIM domains)
2.95 2.717 2.606 18.536
Parathyroid hormone– like
hormone
4.149 2.663 7.965 4.149
Cellular retinoic acid–binding
protein 1
10.132 27.598 19.095 103.292
High-mobility group (nonhistone
chromosomal) protein
isoform I–C
2.643 2.959 2.935 22.683
Amyloid beta 3.031 2.731 2.738 6.443
Osteoglycin (osteoinductive
factor, mimecan)
2.23 3.337 2.079 142.462
Leucine-rich protein, B7 gene 13.253 5.892 9.417 6.874
Carboxylesterase 1 (hydrolyzes
drugs containing ester or
amide bonds)
2.142 9.127 2.831 25.545
Fatty acid –binding protein 4,
adipocyte
2.319 2.208 3.26 3.712
Xlr-related, meiosis regulated 2.196 2.004 2.531 11.276
Gene 33/Mig-6 2.764 2.634 4.126 26.297
AA606367 2.959 2.388 2.549 3.633
Fold change (C26/CI-1040r vs C26).*
*Positive and negative values indicate fold change of upregulation and
downregulation of C26/CI-1040r vs C26, respectively.
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this study, we have isolated and characterized CI-1040–
resistant clones derived from the C26 mouse colon carcino-
ma cell lines after long-term culture in the presence of
increasing concentration of CI-1040. The drug resistance
of C26/CI-1040r cells is likely due to a combined effect of
resistance to both growth inhibition and apoptosis in re-
sponse to CI-1040 treatment. Our results further demon-
strate that C26/CI-1040r cells exhibit elevated expression of
activated K-ras. Consistently, K-ras expression was also
shown to increase in MEK inhibitor–resistant lines derived
from in vivo experiments. Furthermore, overexpression of
active K-ras in C26 parental cells indeed conferred resis-
tance to CI-1040. Collectively, our studies demonstrate that
high-level expression of active K-ras may provide a possible
molecular mechanism for resistance to the MEK inhibitor.
A surprising and interesting observation in our investiga-
tion is that a low concentration of CI-1040 (<2 mM) signifi-
cantly stimulates the growth of the resistant cells but inhibits
the parental cells. The growth-stimulatory effect of CI-1040 is
even more dramatic in clones that have the highest level of
ERK activation (Figure 6). These results demonstrate that
the very high level of ERK activity in the drug-resistant cell
lines may have a growth-inhibitory effect. Partial inhibition of
ERK in these cells may be beneficial for cell growth. Our data
are consistent with previous observations that superactiva-
tion of Ras and Raf could be growth-inhibitory [21–23].
Treatment with 2 mM CI-1040 significantly inhibited ERK
activation in C26/CI-1040r cells (Figure 4A), whereas this
concentration of MEK inhibitor did not inhibit cell growth of
the resistant cells (Figure 1). These results demonstrated
that ERK inhibition is not linearly correlated with the growth
inhibition. Other signaling pathway(s) might contribute to
C26 cell proliferation in the presence of 2 mM CI-1040.
Although ERK activity is required for cell growth, super-
activation of the Ras–ERK pathway can also cause growth-
inhibitory effects. It has been well documented that sus-
tained high-level ERK activation in PC12 cells does not
stimulate cell growth. In contrast, such sustained ERK acti-
vation stimulates differentiation of PC12 cells [24], which can
be blocked by treatment with a MEK inhibitor [25]. Further-
more, a high level of activation of Raf can cause fibroblast
cell growth arrest through induction of p21 [26,28]. In primary
human and mouse fibroblasts, activation of the Ras–ERK
pathway does not induce oncogenic transformation and
instead induces cellular senescence [22]. Therefore, a mod-
erate inhibition of ERK in the drug-resistant cells that
Figure 5. K-ras is activated and overexpressed in CI-1040– resistant cells. (A) K-ras mRNA is upregulated in C26/CI-1040r cells. K-ras signal data are derived from
genechip experiments (Table 1). (B and D) K-ras protein is overexpressed in both in vitro– and in vivo–derived resistant cells. The K-ras from C26 parental or
resistant cells was immunoprecipitated with a pan-ras antibody (SC-35AC) and blotted with K-ras antibody (SC-30). (C) K-ras is activated. The Ras activation
assay was performed with parental and C26/CI-1040r cell lysate using Upstate’s ras activation assay kit.
Table 2. Tumor Growth of C26/PD0325901r Is Resistant to CI-1040.
Complete
Response*
Partial
Responsey
TC
(Days)z
C26 parental 7/10 3/10 12.7
C26/PD0325901r 0/10 0/10 1.4
*A complete response is defined as a tumor that decreased in mass to below
the limit of palpation (62 mg) during the study.
yPartial response represents a tumor that decreased by at least 50% of its
original mass during the study.
zTC is the difference, in days, for the median-treated and control tumors to
reach a fixed evaluation size of 750 mg.
C26 Cells’ Resistance to MEK Inhibition Wang et al. 345
Neoplasia . Vol. 7, No. 4, 2005
have high level ERK activity may contribute to the growth-
stimulating effect of CI-1040 in the resistant cell lines.
One characteristic of cancer cells is their capability to
grow in an anchorage-independent manner. Both the clono-
genic and apoptosis assays suggest that C26/CI-1040r cells
are about 100-fold more resistant to CI-1040 inhibition than
parental C26 cells. In contrast, the sensitivity difference
between C26 and C26/CI-1040r cells is significantly reduced
when cells are grown as monolayers.
Although it has been reported that MEK1/2 activity can
protect cells from apoptosis [27,28], the main function of
MEK revolves around cell growth and proliferation [5,6].
However, in this report, we clearly observed that CI-1040
treatment induces apoptosis in addition to cell cycle arrest.
These observations serve to further demonstrate the func-
tional importance of ERK in cell survival.
Many human cancers contain mutations in Ras and
exhibit activation of the ERK pathway [2,29]. Furthermore,
mutations in many other oncogenes including several growth
factor receptor tyrosine kinases also result in high-level
activation of the ERK pathway. The expectation that all
tumors with activating Ras mutations would be sensitive to
MEK inhibition is debatable in light of the data reported here.
Clearly, resistance to MEK inhibition in C26/CI-1040r cells is
mediated in part by overexpression of Ras. However, it
should be pointed out that exquisite sensitivity to MEK
inhibition has been found for a number of human tumor
xenograft models known to contain ras mutations, such as
the MiaPaCa-2 pancreatic model. In this regard, it is note-
worthy that Hamad et al. [30] reported that the mechanism
of Ras transformation in humans might be distinctly different
from that in mice. Thus, observations reported here on the
molecular mechanism of resistance to MEK inhibition should
be viewed within the context of the murine background of
C26/CI-1040r cells. Further studies are warranted in human
tumors to obtain a better understanding of the relationship of
ras mutations to MEK inhibition sensitivity in the context of
the complex interrelationships of key signaling pathways and
molecules in a given tumor. Derived commonalities from
such studies could well lead to the ability to predict which
patient population would derive the greatest benefit of treat-
ment with a MEK inhibitor.
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